Recently, Libang Enterprise’s Self-developed Second Class New Drug Long-acting Ropivacaine Injection has already been approved for clinical test by SFDA, which is not only another breakthrough after Libang’s self-developed first class new drug LMR-101 and but also the first success of domestic enterprise in the field of sustained release anesthesia injection. It not only relieves the clinician’s worry about cardiotoxicity but also provides more and better choices for the postoperative patients.

As a long-acting analgesic preparation, the single injection of Long-acting Ropivacaine Injection’s analgesia time lasts for 48 hours. It separates the sensory and motor nerve block and it is used around the wound in subcutaneous injection, which is easy to operate and has minor side effect. It will become an ideal emergency analgesic.

Facing the future, driven by innovation, Libang enterprise will take advantage of the pharmaceutical industry chain, adhere to the mission of “Respecting science, Caring for Health” and then move forward in a situation with crisis and reform.